Article

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records Study

2025-12-02

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Ocrelizumab and natalizumab are commonly prescribed high-effectiveness disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS). However, no randomized clinical trial and few real-world studies have directly compared their effectiveness in reducing disability progression. Subtype classification and disability status are critical for multiple scler...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 66d0f075-e31e-55ae-b2b4-76a87dbb4262
DOI: 10.64898/2025.12.01.25341331

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records StudyDOI 10.64898/2025.12.01.25341331Read

Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design ImplicationsSemantic proximity Read

Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare SystemsSemantic proximity Read

Associations of DMT therapies with COVID-19 severity in multiple sclerosisSemantic proximity Read

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort StudySemantic proximity Read

The Austrian MS Database and the Austrian MS Cohort – a national effort towards data harmonization and prospective data collectionSemantic proximity Read

From Fragmented Evidence to a Unified GCC Demyelinating Disease Registry: A Strategic Framework for MS, NMOSD, MOGAD, Optic Neuritis, LETM, and Pediatric Acquired DemyelinationSemantic proximity Read

Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM).Semantic proximity Read

Landscape of MS patient cohorts and registries: Recommendations for maximizing impact.Semantic proximity Read

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple SclerosisSemantic proximity Read

Disease Modifying Therapies and COVID-19 Severity in Multiple SclerosisSemantic proximity Read

Detecting multiple sclerosis disease activity and progression in progress notes from electronic medical records using natural language processing and machine learningSemantic proximity Read

Comparative effectiveness of natalizumab and fingolimod and injectable therapies in patients with pediatric multiple sclerosis: A registry-based retrospective cohort studySemantic proximity Read